Updates on HER2-Directed ADCs Across Solid Tumors - Episode 7

Impact of ADCs on Brain Metastases

, , , ,

A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.

EP. 1: Assessing HER2 Status Across Tumor Types
EP. 2: ADCs Targeting HER2+ Breast Cancer
EP. 3: ADCs Targeting HER2+ Gynecologic Cancers
EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
EP. 5: ADCs Targeting GI Cancers
EP. 6: ADCs Targeting HER2+ Lung Cancer
Now Viewing
EP. 7: Impact of ADCs on Brain Metastases
EP. 8: ADCs Targeting HER2+ GU Cancers
EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
EP. 11: Managing ILD and Pneumonitis Risk From ADCs
EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs
EP. 13: Managing Hematologic AEs Associated with ADC Treatments
EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates
EP. 15: ADC Sequencing
EP. 16: Emerging ADCs in Development
EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
EP. 18: The Future for HER2-Directed ADCs
EP. 19: Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

  • Where do HER2-directed ADCs fit into the overall treatment paradigm? Are most patients being tested for HER2 expression?
    • When and why should T-DXd be considered?